MarketPulse

objective response rate

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Relay Therapeutics

Relay Therapeutics Advances Breast Cancer Drug Combo Toward Phase 3 Trial

Relay Therapeutics reports positive Phase 2 data for zovegalisib triplet combination in metastatic breast cancer, planning Phase 3 launch in early 2027.
PFERLAYPhase 3 trialzovegalisib
GlobeNewswire Inc.GlobeNewswire Inc.··Perspective Therapeutics, Inc.

Perspective Therapeutics Advances Rare Cancer Therapy With 43% Response Rate Data

Perspective Therapeutics reports 43% response rate for neuroendocrine tumor therapy with no serious safety issues, planning 2026 regulatory submissions.
CATXclinical trialcancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Revolution Medicines Advances KRAS G12D Lung Cancer Drug With 52% Response Rate

Revolution Medicines reports promising Phase 1 data for zoldonrasib, showing 52% response rate in previously treated KRAS G12D lung cancer patients with manageable safety profile.
RVMDRVMDWPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kura Oncology's Darlifarnib-Cabozantinib Combo Shows Promise in Resistant Kidney Cancer

Kura Oncology reports darlifarnib plus cabozantinib achieved 44% response rate in cabozantinib-pretreated renal cell carcinoma patients, potentially overcoming drug resistance.
KURAclinical trial dataobjective response rate
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion's Personalized Cancer Vaccine Shows 75% Response Rate in Extended Trial

Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.
MRKEVAXphase 2 trialimmunotherapy
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Regimen Achieves Primary Endpoints in Metastatic Colorectal Cancer Trial

Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.
PFEFDLPJPcolorectal cancerBraftovi